Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Ranbaxy’s $500 Million Settlement Includes Criminal Penalties

May 14 2013

• By Sue Sutter

Related Content

Ranbaxy’s $500 Million GMP Settlement Would Be Second Most Expensive For Rx Manufacturing Violations

Jan 02 2012

Where’s Generic <em>Diovan</em>? Ranbaxy’s Valsartan ANDA In Limbo As Novartis’ Patent Expires

Sep 25 2012

Related Companies

Ranbaxy Laboratories Limited

Pfizer Inc.

Novartis AG

Takeda Pharmaceutical Co. Ltd.

Additional Topics

United States India Asia Pacific Compliance Legal Issues BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window